ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Biotechnology

Healthcare
$10.90 +1.40%

+$0.44 today

Market cap
$563.78M
Beta
1.42
P/E (TTM)
-9.8
EPS (TTM)
-$3.22
52W Low $16.10High $33.62

Volume 2.70M

Average 0.50M

AVBP Total Non-current Assets

All assets not expected to be converted to cash within one year.

ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP

Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026

Total non-current assets falls 98.0% from a year ago

Total non-current assets stood at $595K at the end of Q1 FY2026, down 98.0% from a year earlier and up 118.8% from the prior quarter. Over 3 fiscal years it compounded at +8.8% a year.

Context

  • Total non-current assets amounted to 0.2% of total assets at the end of Q1 FY2026, down 13.6 pp from a year earlier.
  • Total non-current assets increased in 2 of the last 3 fiscal years.

What to watch

Whether total non-current assets keeps falling in the next quarterly balance sheet after a -98.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$595K+118.8% QoQ
Last fiscal yearDec 2025
$272K-99.4% YoY
Year agoMar 2025
$29.71M-98.0% since
Total Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.0%——
1 year-99.4%——
3-year CAGR+8.8%——
5-year CAGR——
10-year CAGR——

Total Non-current Assets history

USD · from the balance sheet

Latest · FY2025
272K USD
Year-over-year change
-99.4%
4-year CAGR
+33.0%

Total Non-current Assets vs competitors

How AVBP compares with its peers on the latest reported figures

  • AVBP's Mar 2026 total non-current assets of $595K is the lowest of the 11 companies compared; the peer median is $153.64M.
  • Its year-over-year change of -98.0% is the lowest of 11, against a peer median of -12.7%.
  • Total non-current assets amounts to 0.2% of total assets for AVBP, versus a peer median of 20.6%.
AVBP Competitors Peer median
Total Non-current Assets for AVBP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EXELExelixis, Inc.Jul 2026$1.24B -17.0%-1.2%49.9%
ERASErasca, Inc.Sep 2026$343.74M +185.3%+16.0%34.4%
IDYAIDEAYA Biosciences, Inc.Mar 2026$334.24M -14.9%+193.4%32.4%
HCMHUTCHMED (China) LimitedDec 2025$185.76M -10.5%-0.7%10.6%
ZLABZai Lab LimitedJun 2026$160.76M +23.6%+16.9%15.0%
ORICORIC Pharmaceuticals, Inc.Mar 2026$146.53M +366.3%+45.4%33.5%
PBYIPuma Biotechnology, Inc.Mar 2026$50.44M -20.8%-15.2%26.2%
NUVBNuvation Bio Inc.Jun 2026$18.07M -24.8%+69.1%2.4%
TYRATyra Biosciences, Inc.Mar 2026$17.43M -7.8%+24.5%4.2%
BDTXBlack Diamond Therapeutics, Inc.Mar 2026$9.96M -51.6%-28.2%7.5%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$595K -98.0%+8.8%0.2%
Peer median (excluding AVBP) $153.64M-12.7%+16.5%20.6%

Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents37.28M163.37M150.39M74.29M45.54M
Short-term Investments000144.57M267.28M
Net Receivables000500K60K
Inventory00000
Other Current Assets5.64M18.92M9.21M7.21M20.02M
Total Current Assets42.95M182.62M159.97M226.98M332.9M
Property, Plant & Equipment (Net)0139K291K154K13K
Goodwill00000
Intangible Assets00000
Long-term Investments00047.68M0
Tax Assets00000
Other Non-current Assets87K72K2.84M126K259K
Total Non-current Assets87K211K3.13M47.96M272K
Total Assets43.04M182.83M163.1M274.94M333.17M
Account Payables293K3.09M4.53M3.78M5.93M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities0004.16M6.55M
Total Current Liabilities1.82M8.36M11.62M17.27M25.95M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities011K177K14K0
Total Liabilities1.82M8.37M11.8M17.29M25.95M
Common Stock0003K4K
Retained Earnings(51.61M)(88.51M)(157.85M)(238.33M)(404.64M)
Accumulated OCI(2K)00(211K)14K
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity41.22M174.46M151.3M257.65M307.22M
Total Debt0139K317K176K14K
Net Debt(37.28M)(163.23M)(150.07M)(74.12M)(45.53M)

ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Intrinsic Alpha fair value

Locked

Current Price

$10.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.